Untitled

doi:10.13040/ijpsr.0975-8232.10(7).3241-49

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several methods have been reported in the literature for the estimation of ETO, MOX and NAL in their pharmaceutical dosage form and/or biological fluids; for ETO: spectrophotometric [8], spectrofluorimetric (SF) [9], electrochemical [10,11], high-performance thin-layer chromatography (HPTLC) [12], high-performance liquid chromatography (HPLC) [13][14][15][16][17], gas chromatography (GC) [18] and capillary electrophoresis (CP) [19]; for MOX: spectrophotometric [20,21], SF [22], electrochemical [23], HPTLC [24], HPLC [25][26][27] and CP [28] and for NAL spectrophotometric [29][30][31], SF [31,32], flow injection analysis [33,34], HPLC [35][36][37] and GC [38]. These presented methods did not guide the monitoring of these three drugs in the biological matrices.…”

Section: Introductionmentioning

confidence: 99%

Eco-friendly fluorimetric approaches for the simultaneous estimation of the co-administered ternary mixture: etoposide, moxifloxacin and nalbuphine

2021

View full text Add to dashboard Cite

Antineoplastic drugs, etoposide (ETO), are widely used in leukaemia. A patient with leukaemia has a relative infection with pneumonia treated by fluoroquinolones as moxifloxacin HCL (MOX). Because opioid analgesic as nalbuphine HCL (NAL) does not have a ceiling dose, it is used to manage the distasteful sensory in leukaemia. Consequently, green methods for synchronous spectrofluorimetric quantification of a ternary mixture of ETO, MOX and NAL were developed. The first approach relies simply on the estimation of MOX at 371 nm by conventional synchronous fluorimetric technique (Δ λ of 60 nm). The second approach depends on applying the first derivative synchronous fluorimetric technique (Δ λ of 60 nm) for simultaneous estimation of ETO and NAL at 257 and 273 nm, respectively. A good linear correlation was obtained in the ranges of 0.04–0.40, 0.10–1.00 and 0.50–5.00 µg ml −1 for MOX, ETO and NAL, respectively. Moreover, the proposed approaches were successfully applied for the estimation of the studied drugs in the pharmaceutical dosage forms. Additionally, the synchronous assessment of ETO, MOX and NAL in the spiked human urine was successfully attained by the facile protein precipitation technique. The mean % recoveries in spiked human urine were 99.49, 98.07 and 98.48 for MOX, ETO and NAL, respectively.

show abstract